View Filing Data

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	OptimizeRx Corp
Amendment Flag	false
Entity Central Index Key	0001448431
Document Type	S-1
Trading Symbol	OPRX
Current Fiscal Year End Date	--12-31
Document Period End Date	Mar. 31, 2018
Entity Filer Category	Smaller Reporting Company

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current Assets
Cash and cash equivalents	$ 4,298,619	$ 5,122,573	$ 7,034,647
Accounts receivable	1,871,255	2,257,276	1,951,811
Accounts receivable - related party	1,974,143	1,173,614	1,108,585
Prepaid expenses	191,413	255,428	80,820
Total Current Assets	8,335,430	8,808,891	10,175,863
Property and equipment, net	157,608	167,305	173,649
Other Assets
Patent rights, net	621,793	638,766	772,394
Web development costs, net	152,493	143,730	351,804
Security deposit	5,049	5,049	5,049
Total Other Assets	779,335	787,545	1,129,247
TOTAL ASSETS	9,272,373	9,763,741	11,478,759
Current Liabilities
Accounts payable - trade	133,870	457,289	369,214
Accrued expenses	549,656	953,947	288,268
Revenue share payable	898,478	1,177,136	2,495,059
Revenue share payable - related party		447,670	127,458
Deferred revenue	856,914	507,160	386,581
Total Liabilities	2,438,918	3,543,202	3,666,580
Stockholders' Equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no issued and outstanding at March 31, 2018 or December 31, 2017
Common stock, $0.001 par value, 500,000,000 shares authorized, 9,878,944 and 9,772,694 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively	9,879	9,773	9,906
Stock warrants	1,286,424	1,286,424	2,294,416
Additional paid-in-capital	36,231,480	35,287,464	33,766,950
Accumulated deficit	(30,694,328)	(30,363,122)	(28,259,093)
Total Stockholders' Equity	6,833,455	6,220,539	7,812,179
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 9,272,373	$ 9,763,741	$ 11,478,759

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000	500,000,000
Common stock, shares issued	9,878,944	9,772,694	9,906,289
Common stock, shares outstanding	9,878,944	9,772,694	9,906,289

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
NET REVENUE
Revenue	$ 2,781,621	$ 1,400,318	$ 8,431,208	$ 6,209,051
Revenue - Related Party	1,330,616	751,755	3,696,214	1,542,411
TOTAL NET REVENUE	4,112,237	2,152,073	12,127,422	7,751,462
REVENUE SHARE EXPENSE	2,008,092	1,381,733	6,174,614	3,411,396
GROSS MARGIN	2,104,145	770,340	5,952,808	4,340,066
Operating expenses
Stock-based compensation			902,389	559,301
Depreciation and amortization	54,473	70,973	324,551	235,284
Lawsuit settlement				50,000
Other general and administrative expenses			6,855,834	5,076,993
OPERATING EXPENSES	2,295,341	1,660,778	8,082,774	5,921,578
LOSS FROM OPERATIONS	(191,196)	(890,438)	(2,129,966)	(1,581,512)
OTHER INCOME (EXPENSE)
Interest Income	2,017	7,756	25,937	42,309
Interest Expense
TOTAL OTHER INCOME (EXPENSE)	2,017	7,756	25,937	42,309
LOSS BEFORE PROVISION FOR INCOME TAXES	(189,179)	(882,682)	(2,104,029)	(1,539,203)
PROVISION FOR INCOME TAXES
NET LOSS	$ (189,179)	$ (882,682)	$ (2,104,029)	$ (1,539,203)
WEIGHTED AVERAGE SHARES OUTSTANDING
BASIC AND DILUTED	9,786,027	9,906,289	9,819,753	9,902,639
NET LOSS PER SHARE
BASIC AND DILUTED	$ (0.02)	$ (0.09)	$ (0.21)	$ (0.16)

Consolidated Statement of Stockholders' Equity - USD ($)	Total	Common Stock	Stock Warrants	Additional Paid-in Capital	Stock Payable	Deferred Stock Compensation	Accumulated Deficit
Balance at Dec. 31, 2015	$ 8,942,496	$ 9,677	$ 2,329,508	$ 32,204,853	$ 1,132,148	$ (13,800)	$ (26,719,890)
Balance, shares at Dec. 31, 2015		9,676,974
Issuance of stock options to employees	384,126			384,126
Issuance of common stock: for services	51,375	$ 16		51,359
Issuance of common stock: for services, shares		16,667
Issuance of common stock: for cash	449,500	$ 128		449,372
Issuance of common stock: for cash, shares		128,063
Issuance of common stock: for options		$ 35		(35)
Issuance of common stock: for options, shares		34,585
Issuance of common stock: for litigation settlement	110,000	$ 33		109,967
Issuance of common stock: for litigation settlement, shares		33,333
Issue shares for stock payable		$ 17		94,483	(94,500)
Issue shares for stock payable, shares		16,667
Shares redeemed for cash	(599,915)			437,733	(1,037,648)
Expiration of Warrants			(35,092)	35,092
Expense consulting services	13,800					13,800
Net loss for the year	(1,539,203)						(1,539,203)
Balance at Dec. 31, 2016	7,812,179	$ 9,906	2,294,416	33,766,950			(28,259,093)
Balance, shares at Dec. 31, 2016		9,906,289
Issuance of stock options to employees	815,014			815,014
Issuance of common stock: for services	87,375	$ 25		87,350
Issuance of common stock: for services, shares		25,000
Issuance of common stock: for options		$ 8		(8)
Issuance of common stock: for options, shares		8,071
Shares redeemed for cash	(390,000)	$ (166)		(389,834)
Shares redeemed for cash, shares		(166,666)
Expiration of Warrants			(1,007,992)	1,007,992
Net loss for the year	(2,104,029)						(2,104,029)
Balance at Dec. 31, 2017	$ 6,220,539	$ 9,773	$ 1,286,424	$ 35,287,464			$ (30,363,122)
Balance, shares at Dec. 31, 2017		9,772,694

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ (189,179)	$ (882,682)	$ (2,104,029)	$ (1,539,203)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	54,473	70,973	324,551	235,284
Loss on disposal of assets			65,738
Stock and options issued for services	497,122	129,444	815,014	384,126
Stock-based compensation			87,375	175,175
Changes in:
Accounts receivable	(414,508)	253,074	(305,465)	514,514
Accounts receivable related party			(65,029)	(727,460)
Prepaid expenses	64,015	(67,761)	(174,608)	(10,197)
Accounts payable	(323,419)	161,228	88,075	(205,977)
Revenue share payable	(279,328)	(673,730)	(1,317,923)	177,254
Revenue share payable - related party			320,212	89,655
Accrued expenses	(404,291)	(230,975)	665,679	281,285
Deferred revenue	207,727	943,193	120,579	159,579
NET CASH USED IN OPERATING ACTIVITIES	(787,388)	(297,236)	(1,479,831)	(465,965)
CASH FLOWS FROM INVESTING ACTIVITIES:
Equipment	(3,803)	(16,146)	(42,243)	(178,434)
Development costs	(32,763)
Patent rights				(7,268)
Intangible Assets				(163,836)
NET CASH USED IN INVESTING ACTIVITIES	(36,566)	(16,146)	(42,243)	(349,538)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock				449,500
Redemption of common stock			(390,000)	(806,915)
NET CASH USED IN FINANCING ACTIVITIES			(390,000)	(357,415)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(823,954)	(313,382)	(1,912,074)	(1,172,918)
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD	5,122,573	7,034,647	7,034,647	8,207,565
CASH AND CASH EQUIVALENTS - END OF PERIOD	4,298,619	6,721,265	5,122,573	7,034,647
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest
Cash paid for income taxes
Non-cash issuance of shares to WPP	$ 447,000

Nature of Business and Basis of Presentation	3 Months Ended	12 Months Ended
Nature of Business and Basis of Presentation	Mar. 31, 2018	Dec. 31, 2017
Nature of Business and Basis of Presentation [Abstract]
NATURE OF BUSINESS AND BASIS OF PRESENTATION	NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION We are a leading provider of digital health messaging via electronic health records (EHRs), providing a direct channel for pharmaceutical companies to communicate with healthcare providers. Our cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education and critical clinical information. Our network is comprised of leading EHR platforms and provides more than half a million healthcare providers access to these benefits within their workflow at the point of care. The consolidated financial statements for the three months ended March 31, 2018 and 2017 have been prepared by us without audit pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. In the opinion of management, all adjustments necessary to present fairly our financial position, results of operations, and cash flows as of March 31, 2018 and 2017, and for the periods then ended, have been made. Those adjustments consist of normal and recurring adjustments. The consolidated balance sheet as of December 31, 2017, has been derived from the audited consolidated balance sheet as of that date. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, as filed with the U.S. Securities and Exchange Commission. The results of operations for the three months ended March 31, 2018, are not necessarily indicative of the results to be expected for the full year. Certain reclassifications have been made in the prior period’s consolidated financial statements to conform to the current period’s presentation.	NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS OptimizeRx Corporation is a leading provider of digital health messaging via electronic health records (EHRs), providing a direct channel for pharmaceutical companies to communicate with healthcare providers. The company’s cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education and critical clinical information. The company’s network is comprised of leading EHR platforms and provides more than half a million healthcare providers access to these benefits within their workflow at the point of care. The company was originally formed as Optimizer Systems, LLC in the State of Michigan on January 31, 2006. It converted its form to a corporation on October 22, 2007 and changed its name to OptimizeRx Corporation. On April 14, 2008, RFID, Ltd., a Colorado corporation, consummated a reverse merger by entering into a share exchange agreement with the stockholders of OptimizeRx Corporation, pursuant to which the stockholders of OptimizeRx Corporation exchanged all of the issued and outstanding capital stock of OptimizeRx Corporation for 1,256,958 shares of common stock of RFID, Ltd., representing 100% of the outstanding capital stock of RFID, Ltd. As of April 30, 2008, RFID’s officers and directors resigned their positions and RFID changed its business to OptimizeRx’s business. On April 15, 2008, RFID, Ltd.’s corporate name was changed to OptimizeRx Corporation. On September 4, 2008, a migratory merger was completed, thereby changing the state of incorporation from Colorado to Nevada, resulting in the current corporate structure, in which OptimizeRx Corporation, a Nevada corporation, is the parent corporation, and OptimizeRx Corporation, a Michigan corporation, is its wholly-owned subsidiary (together, “OptimizeRx” and “the Company”).

New Financial Accounting Standards	3 Months Ended
New Financial Accounting Standards	Mar. 31, 2018
New Financial Accounting Standards [Abstract]
NEW FINANCIAL ACCOUNTING STANDARDS	NOTE 2 – NEW FINANCIAL ACCOUNTING STANDARDS On January 1, 2018, we adopted the new accounting standard ASC 606, Revenue from Contracts with Customers, and all of the related amendments (“new revenue standard”). We recorded the change, which was immaterial, related to adopting the new revenue standard using the modified retrospective method. Under this method, we recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of retained earnings. This results in no restatement of prior periods, which continue to be reported under the accounting standards in effect for those periods. We expect the impact of the adoption of the new revenue standard to continue to be immaterial on an ongoing basis. We have applied the new revenue standard to all contracts as of the date of initial application. The overwhelming majority of our revenue continues to be recognized when transactions occur, such as the delivery of a message. We previously recognized revenue related to set-ups when a program launched, and all related activities had been accomplished. Under the new revenue standard, we are recognizing revenue related to these set ups over the term of the initial contract. Since set up fees are generally small relative to the size of the overall contract and because most contracts are for a year or less, the impact of this change is immaterial. The impact of recording this change as of January 1, 2018 resulted in an increase in deferred revenue of $142,027 at that date and a corresponding decrease in retained earnings as well. The impact of adopting the new revenue standard in 2018 resulted in lower revenues in the three months ended March 31, 2018. Had the new revenue standard not taken effect, our revenues for the period would have been higher by $117,911 and deferred revenues lower by $117,911. All of these revenues are expected to be recognized by December 31, 2018, so the primary effect of the new revenue standard is to shift revenues between quarters by immaterial amounts.

Stockholders' Equity	3 Months Ended
Stockholders' Equity	Mar. 31, 2018
Stockholders' Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 3 – STOCKHOLDERS’ EQUITY In both March 2018 and 2017, we issued 6,250 shares of our common stock to our independent directors in connection with our Director Compensation Plan, which calls for issuance of 6,250 shares per quarter to each independent director. These shares were valued at $28,875 and $15,375 at March 31, 2018 and 2017, respectively. In March 2018, we issued 100,000 shares of common stock to a subsidiary of WPP, one of the world’s largest advertising companies, and a shareholder, in full payment of all amounts due under a comarketing agreement that covered certain WPP agencies, whereby we shared a portion of our revenue with those agencies related to programs awarded to us by those agencies. The shares were valued at $447,000, the market value of the stock on the date of issuance. The amount due was recorded as a liability in revenue share payable at December 31, 2017. Basic and diluted earnings per share are the same in both periods. The number of common shares potentially issuable related to dilutive securities that were excluded from the diluted loss per common share calculation was approximately 604,172, because they are anti-dilutive, as a result of a net loss for the quarter ended March 31, 2018.

Share Based Payments - Options

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Share Based Payments - Options [Abstract]

SHARE BASED PAYMENTS - OPTIONS

NOTE 4 – SHARE BASED PAYMENTS – OPTIONS

We use the fair value method to account for stock based compensation. We recorded $468,247 and $114,069 in compensation expense in the three months ended March 31, 2018 and 2017, respectively, related to options issued under our stock-based incentive compensation plan. This includes expense related to options issued in prior years for which the requisite service period for those options includes the current year as well as options issued in the current year. The fair value of these instruments was calculated using the Black-Scholes option pricing model. The assumptions used in this model were similar to the assumptions set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 related to grants in 2017. As also discussed in the 10-K, we increased the shares of common stock authorized under our stock option plan during the quarter to 1,833,333 million shares.

NOTE 11 – STOCK OPTIONS

The Company sponsors a stock-based incentive compensation plan known as the 2013 Equity Compensation Plan (the “Plan”), which was established by the Board of Directors of the Company in June 2013. A total of 500,000 shares were initially reserved for issuance under the Plan. The Plan was amended in 2016 to increase the authorized shares to 1,333,333 shares and again in 2018 to increase the authorized shares to 1,833,333. A total of 1,368,750 options were outstanding at December 31, 2016. In addition, a total of 245,035 restricted shares were granted in 2014 and 2015, but not issued at the time. A total 228,338 of these shares were redeemed for cash in 2016, and 16,667 of these shares were issued in 2016. As of December 31, 2017, the Company has no remaining restricted shares owed. The Company had no remaining shares available to grant under the Plan at December 31, 2017.

The Plan allows the Company to grant incentive stock options, non-qualified stock options, stock appreciation right, or restricted stock. The incentive stock options are exercisable for up to ten years, at an option price per share not less than the fair market value on the date the option is granted. The incentive stock options are limited to persons who are regular full-time employees of the Company at the date of the grant of the option. Non-qualified options may be granted to any person, including, but not limited to, employees, independent agents, consultants and attorneys, who the Company’s Board or Compensation Committee believes have contributed, or will contribute, to the success of the Company. Non-qualified options may be issued at option prices of less than fair market value on the date of grant and may be exercisable for up to ten years from date of grant. The option vesting schedule for options granted is determined by the Compensation Committee of the Board of Directors at the time of the grant. The Plan provides for accelerated vesting of unvested options if there is a change in control, as defined in the Plan.

Prior to establishment of the Plan, the Board granted options under terms similar to those described in the preceding paragraphs. A total of 8,333 options were outstanding at December 31, 2016 that were granted prior to the establishment of the 2013 Plan, but those options expired in 2017.

The compensation cost that has been charged against income related to options for the years ended December 31, 2017 and 2016, was $815,014 and $384,126, respectively. No income tax benefit was recognized in the income statement and no compensation was capitalized in any of the years presented.

The Company had the following option activity during the years ended December 31, 2017 and 2016:

	Number of Options			Weighted average exercise price		Weighted average remaining contractual life (years)		Aggregate intrinsic value $
Outstanding, January 1, 2016		538,333		$	3.27
Granted - 2016		680,000		$	3.27
Exercised - 2016		(161,666	)	$	2.67
Expired – 2016		(16,667	)	$	3.24
Outstanding, December 31, 2016		1,040,000		$	3.36		3.6
Granted – 2017		480,417		$	2.88
Exercised – 2017		(43,333	)	$	3.81
Expired – 2017		(108,334	)	$	4.02
Outstanding, December 31, 2017		1,368,750		$	3.12		3.2	$	2,173,700
Exercisable, December 31, 2017		630,417		$	3.06		2.9	$	1,035,900

Of the options outstanding at December 31, 2016, 406,667 were exercisable with a weighted average contractual life of 1.1 years and the remaining 633,333 were non-vested.

The table below shows the expiration date and exercise price of the options outstanding at December 31, 2017.

Number of Options	Exercise Price	Expiration Date
200,000	$2.46	03/31/22
50,000	$3.00	10/30/18
378,333	$3.15	03/03/19
500,000	$3.21	02/22/21
166,667	$3.45	07/28/21
6,667	$3.51	11/01/22
33,333	$3.66	03/03/19
10,417	$4.71	12/31/22
3,333	$5.55	01/29/19

Related Party Transactions

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

RELATED PARTY TRANSACTIONS

NOTE 5 – RELATED PARTY TRANSACTIONS

As described in more detail in Note 3, Stockholders Equity, we issued 100,000 shares of our common stock to a subsidiary of WPP, a shareholder that owns approximately 20% of our common shares.

NOTE 8 – RELATED PARTY TRANSACTIONS

During the year ended December 31, 2010, the Company acquired the technical contributions and assignment of all exclusive rights to and for a key patent in process at the time from a former CEO in exchange for 100,000 shares of common stock to be granted at the discretion of the seller and 66,667 stock options, valued at $360,000, which expired in April 2015. The shares were valued on the grant date at $570,000 and were recorded as a payable to the related party. In 2016, the obligation to issue those shares was redeemed for a payment of $363,000 in cash.

During the year ended December 31, 2015, WPP, plc made a strategic investment in the Company and is a shareholder that owns approximately 20% of the shares of the Company.

The following table sets forth the activity between the Company and WPP

	2017		2016
Total billings to WPP Agencies	$	3,554,168	$	2,613,942
Revenue recognized from WPP Agencies	$	3,696,214	$	1,542,411
Accounts receivable from WPP Agencies	$	1,173,614	$	1,108,585
Rebates given to WPP Agencies	$	33,249	$	24,519
Marketing services purchased from WPP Agencies	$	54,762	$	190,686
Accounts payable to WPP Agencies	$	-	$	12,600
Revenue share expense recorded to WPP Agencies	$	401,596	$	177,372
Revenue share expenses owed to WPP Agencies	$	447,670	$	127,458

Contingencies

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Contingencies [Abstract]

CONTINGENCIES

NOTE 6 – CONTINGENCIES

Litigation

The company is not involved in any legal proceedings.

NOTE 15 – COMMITMENTS AND CONTINGENT LIABILITIES

Legal

The Company is not involved in any legal proceedings.

Revenue-share contracts

The Company has contacts with various Electronic Health Records systems and ePrescribe platforms, whereby we agree to share a portion of the revenue we generate for eCoupons distributed through their networks. These contracts grant audit rights related to the payments to our partners, and in some cases would require us to pay for the audit if the audit determined there was an underpayment and the underpayment meets certain thresholds, such as 10%.

Operating Leases

The Company initially signed the lease for its current office space located in Rochester Michigan on December 1, 2011. That lease expired November 30, 2016 and the Company signed a new lease for the same space. The current lease is a three-year lease beginning December 1, 2016, with options for up to an additional 6 years. The rent is payable monthly at rates of $6,232, $6,308, and $6,384 per month for years 1, 2, and 3 of the lease, respectively. The monthly rates for the option years range from $6,384 per month to $6,688 per month for the option years 4 through 9 of the lease. If the Company fails to exercise its option for option years 4 and 5, a least termination payment of $7,300 will be due at the end of the initial 3-year term.

The Company also has month to month leases on shared office spaces in Cambridge Massachusetts and Nashville, Tennessee, payable at rates of $2,700 per month and $1,370 per month, respectively.

Minimum annual rent payments are as follows for the remaining term of the leases:

Year ended December 31:
2018		75,772
2019		70,224
Total lease commitment	$	145,996

Allscripts Agreement

In 2015, we signed an amendment to our Allscripts agreement whereby we became its exclusive eCoupon supplier and Allscripts agreed to integrate our eCoupon functionality into its Touchworks platform. Under the terms of this agreement, we agreed to pay $900,000 in two installments. The first installment of $250,000 was due and paid in November 2015. The second installment of $650,000 originally was due when the e-Coupon functionality was launched on a widespread basis in the Touchworks platform, which occurred February 28, 2017. A payment of $325,000 was made at the time and the remaining amount due was extended until October, 2018.

Hosting agreement

The Company has an agreement with a third party to host and administer its software through March 31, 2018 at a rate of $24,230 per month for a total of $72,690 for the three-month period. That agreement was terminated in December 2017 with an effective date of March 31, 2018 in conjunction with moving to a more cost-effective solution and in connection with that termination, the Company will make additional payments of $220,440

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2017

Summary of Significant Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars. The Company has adopted a December 31 fiscal year-end.

Principles of Consolidation

The financial statements reflect the consolidated results of OptimizeRx Corporation (a Nevada corporation) and its wholly owned subsidiary, OptimizeRx Corporation (a Michigan corporation). All material inter-company transactions have been eliminated in the consolidation.

Cash and Cash Equivalents

For purposes of the accompanying financial statements, the Company considers all highly liquid instruments with an initial maturity of three months or less to be cash equivalents.

Fair Value of Financial Instruments

The fair value of cash, accounts receivable, prepaid expenses, accounts payable, accounts payable – related party, accrued expenses and deferred revenue approximates the carrying amount of these financial instruments due to their short-term nature.

Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including our own credit risk.

In addition to defining fair value, the disclosure requirements around fair value establish a fair value hierarchy for valuation inputs, which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

Level 1 – Inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

Level 2 – Inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The Company’s stock options and warrants are valued using level 3 inputs.

The carrying value of the Company’s financial assets and liabilities, which consist of cash, accounts receivable, prepaid expenses, patent rights, web development costs, accounts payable, accounts payable – related party, accrued expenses and deferred revenue, are valued using level 1 inputs. The Company believes that the recorded values approximate their fair value due to the short maturity of such instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, exchange or credit risks arising from these financial instruments.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates. Because the Company’s customers are primarily large well-capitalized companies, historically there has been very little bad debt expense. Bad debt expense was $0 for each of the years ended December 31, 2017 and 2016. The allowance for doubtful accounts was $0 as of both December 31, 2017 and 2016.

Property and Equipment

Property and equipment are stated at cost and are being depreciated over their estimated useful lives of three to five years for office equipment and three years for computer equipment using the straight-line method of depreciation for book purposes. Maintenance and repair charges are expensed as incurred.

Intangible Assets

Intangible assets are stated at cost and are being amortized over their estimated useful lives of seventeen years for patents and three to four years for software and websites using the straight-line method.

Revenue Recognition and Revenue Share Expense

Revenue is recognized when it is earned. Revenues are primarily generated from content delivery activities in which the Company delivers financial or brand messaging through a distribution network of ePrescribers and Electronic Health Record technology providers (channel partners), or from reselling services that complement the business for other partners.

The Company recognizes setup fees that are required for integrating client offerings and campaigns into the rule-based content delivery system and network upon completion of the setup when the client’s campaign is ready to launch within the system. As the messaging is distributed through the platform and network of channel partners (a transaction), these transactions are recorded, and revenue is recognized, at the time of distribution. Revenue for transactions can be realized based on a price per message, a price per redemption, or as a flat fee over a period of time, depending on the client contract. Additionally, the Company also recognizes revenue for providing program performance reporting and maintenance, either by the Company directly delivering reports or by providing access to its online reporting portal that the client can utilize. These fees are charged monthly and recognized as recurring monthly revenue.

In some instances, the Company also resells products and or services that are available through channel partners on a commission basis, and that are complementary to the core business and client base. In these instances, net revenue is recognized based on the commission based revenue split that the Company receives. In instances where the Company resells services and have all financial risk and significant operation input and risk, the Company records the revenue gross.

Based on the volume of transactions that are delivered through the channel partner network, the Company provides a revenue share to compensate the partner for their promotion of the campaign. Revenue shares are a negotiated percentage of the transaction fees and can also be specific to special considerations and campaigns. In addition, the Company pays revenue share to ConnectiveRx (formerly LDM/PDR) as a result of a 2014 legal settlement in an amount equal to the greater of 10% of financial messaging distribution revenues generated through the network, or $0.37 per financial message distributed through our network. The contractual amount due to the channel partners is recorded as an expense at the time the eCoupon is distributed.

Income Taxes

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

The Company recognizes the tax benefit from uncertain tax positions if it is more likely than not that the tax positions will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefit is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. It is the Company’s policy to include interest and penalties related to tax positions as a component of income tax expense.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the carrying value of assets, depreciable and amortizable lives of tangible and intangible assets, the carrying value of liabilities, the amount of revenue to be billed, and the timing of revenue recognition and related revenue share expenses. Actual results could differ from these estimates.

Concentration of Credit Risks

The Company maintains its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences financial difficulties.

Research and Development

The Company expenses research and development expenses as incurred. Our research efforts are focused on understanding the market dynamics that have the potential to affect the business and increase revenue in both the short and long term. Our primary goal is to increase revenue by helping patients better afford and access the medicines their doctors prescribe, as well as other healthcare products and services they need. Based on this, the Company continually seeks ways to improve its technology to enhance user experiences, and to develop new services and solutions for its customers.

Share-based Payments

The Company uses the fair value method to account for stock-based compensation. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered. The fair value of each award is estimated on the date of each grant. For restricted stock, the fair market value is based on the market value of the stock granted on the date of the grant. For options, it is estimated using the Black-Scholes option pricing model that uses the assumptions noted in the following table. Estimated volatilities are based on the historical volatility of the Company’s stock over the same period as the expected term of the options. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The Company uses historical data to estimate option exercise behavior and to determine this term. The risk free rate used is based on the U.S. Treasury yield curve in effect at the time of the grant using a time period equal to the expected option term. The Company has never paid dividends and does not expect to pay any dividends in the future.

	2017	2016

Expected dividend yield	0%	0%
Risk free interest rate	1.47% - 1.81%	0.86%-1.15%
Expected option term	3.5 – 5 years	4.5 years
Turnover/forfeiture rate	0%	0%
Expected volatility	65%-78%	91% - 99%

The Black-Scholes option valuation model and other existing models were developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. These option valuation models require the input of, and are highly sensitive to, subjective assumptions including the expected stock price volatility. OptimizeRx’s stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions could materially affect the fair value estimate.

Loss Per Common and Common Equivalent Share

The computation of basic earnings per common share is computed using the weighted average number of common shares outstanding during the year. The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year plus common stock equivalents, which would arise from the exercise of warrants outstanding using the treasury stock method and the average market price per share during the year. The number of common shares potentially issuable upon the exercise of certain options and warrants that were excluded from the diluted loss per common share calculation was approximately 163,067, because they are anti-dilutive, as a result of a net loss for the year ended December 31, 2017. As described in Notes 11 and 12, the Company had options and warrants outstanding as indicated in the table below.

	2017		2016

Options		1,368,750		1,040,000
Warrants		348,194		681,528
Weighted average exercise price	$	3.18	$	4.02

Impairment of Long-Lived Assets

The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.

Recently Issued Accounting Guidance

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. The Company will adopt ASU 2016-02 in its first quarter of 2019. While the Company is currently evaluating the timing and impact of adopting ASU 2016-02, currently the Company anticipates no material impact to its Consolidated Statements of Operations. However, the ultimate impact of adopting ASU 2016-02 will depend on the Company’s lease portfolio as of the adoption date.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to customers.

Subsequently, the FASB has issued the following standards related to ASU 2014-09: ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (“ASU 2016-08”); ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing (“ASU 2016-10”); ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”); and ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers (“ASU 2016-20”). The Company must adopt ASU 2016-08, ASU 2016-10, ASU 2016-12 and ASU 2016-20 with ASU 2014-09 (collectively, the “new revenue standards”).

The new revenue standards may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The Company will adopt the new revenue standards in its first quarter of 2018. The new revenue standards are not expected to have a material impact on the amount and timing of revenue recognized in the Company’s consolidated financial statements.

Prepaid Expenses

12 Months Ended

Dec. 31, 2017

Prepaid Expenses [Abstract]

PREPAID EXPENSES

NOTE 3 – PREPAID EXPENSES

Prepaid expenses consisted of the following as of December 31, 2017 and 2016:

	2017		2016
Insurance	$	43,764	$	43,608
Rent		8,539		7,212
EHR access fees		203,125		-
Legal		-		30,000
Total prepaid expenses	$	255,428	$	80,820

Property and Equipment

12 Months Ended

Dec. 31, 2017

Property and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 4 – PROPERTY AND EQUIPMENT

The Company owned equipment recorded at cost which consisted of the following as of December 31, 2017 and 2016:

	2017		2016
Computer equipment	$	83,079	$	66,433
Furniture and fixtures		158,502		132,905
Subtotal		241,581		199,338
Accumulated depreciation		74,276		(25,689	)
Property and equipment, net	$	167,305	$	173,649

Depreciation expense was $48,587 and $22,414 for the years ended December 31, 2017 and 2016, respectively.

Web-Based Technology

12 Months Ended

Dec. 31, 2017

Web-Based Technology [Abstract]

WEB-BASED TECHNOLOGY

NOTE 5 – WEB-BASED TECHNOLOGY

The Company has capitalized costs in developing its technology, which consisted of the following as of December 31, 2017 and 2016:

	2017			2016
OptimizeRx consumer web-based technology	$	154,132		$	154,133
OptimizeRx EHR integrated technology		1,304,230			1,304,230
Subtotal		1,458,362			1,458,363
Accumulated amortization		(1,314,632	)		(1,106,559	)
Web-based technology, net	$	143,730		$	351,804

Amortization is recorded using the straight-line method over periods of up to five years. The consumer web-based technology has no carrying value at either December 31, 2016 or 2017. Amortization expense for the technology costs was $208,074 and $152,502 for the years ended December 31, 2017 and 2016, respectively. Amortization expense related to these assets is expected to be $91,039 in 2018 and $52,691 in 2019 to completely amortize the December 31, 2017 carrying value.

Patent and Trademarks

12 Months Ended

Dec. 31, 2017

Patent and Trademarks [Abstract]

PATENT AND TRADEMARKS

NOTE 6 – PATENT AND TRADEMARKS

On April 26, 2010, the Company acquired the technical contributions and assignment of all exclusive rights to and for a key patent from the former CEO of the Company in exchange for 100,000 shares of common stock, valued at $570,000 and 66,667 stock options, valued at $360,000.

The Company has capitalized costs in purchasing and defending its patent, which consisted of the following as of December 31, 2017 and 2016:

	2017			2016
Patent rights and intangible assets	$	930,000		$	930,000
Patent defense costs		172,457			172,457
New patents and trademarks		-			65,738
Subtotal		1,102,457			1,168,165
Accumulated amortization		(463,691	)		(395,801	)
Patent rights and intangible assets, net	$	638,766		$	772,394

The Company began amortizing the patent, using the straight-line method over the estimated useful life of 17 years, once it was put into service in July 2010. In 2013, the Company began incurring costs related to defense of the patent. These costs have been capitalized and will be amortized using the straight-line method over the remaining useful life of the original patent. Amortization expense was $67,890 and $67,758 for the years ended December 31, 2017 and 2016, respectively. We expect our amortization expense related to these patents to be $67,890 for each of the years from 2018 through 2022.

Deferred Revenue	12 Months Ended
Deferred Revenue	Dec. 31, 2017
Deferred Revenue [Abstract]
DEFERRED REVENUE	NOTE 7 – DEFERRED REVENUE The Company has several signed contracts with customers for the distribution of financial messaging, or other services, which include payment in advance. The payments are not recorded as revenue until the revenue is earned under its revenue recognition policy discussed in Note 2. Deferred revenue was $507,160 and $386,581 as of December 31, 2017 and 2016, respectively.

Preferred Stock	12 Months Ended
Preferred Stock	Dec. 31, 2017
Preferred Stock [Abstract]
PREFERRED STOCK	NOTE 9 – PREFERRED STOCK The Company has 10,000,000 shares of preferred stock, $.001 par value per share, authorized as of December 31, 2017. Of those shares, 1,000 were designated as Series A and Series B. There were no shares outstanding at any time during the periods covered by these financial statements. The Series A and B designations were transaction specific in 2008 and 2010 and were redeemed in 2014. When outstanding, the shares had a liquidation preference and bore dividends at a rate of 10%, payable in cash or stock, but are no longer applicable. The Company intends to remove the designations in 2018.

Common Stock	12 Months Ended
Common Stock	Dec. 31, 2017
Common Stock [Abstract]
COMMON STOCK	NOTE 10 – COMMON STOCK The Company had 500,000,000 shares of common stock, $.001 par value per share, authorized as of December 31, 2017. There were 9,772,694 and 9,906,289 shares of common stock issued and outstanding at December 31, 2017 and 2016, respectively. In 2017, the Company purchased and cancelled 166,666 shares held by the previous CEO at a price of $2.34 per share for a total payment of $390,000. In 2017 the Company issued 8,071 shares in connection with the exercise of employee stock options by former employees. The options were exercised on a net settled basis and no cash proceeds were received. The Company has a Director Compensation plan covering its independent non-employee Directors. A total of 25,000 and 16,667 shares were granted and issued in the years ended December 31, 2017 and 2016, respectively in connection with this compensation plan. These shares were valued at $87,375 and $51,375, respectively. In 2016, we issued 128,063 shares of common stock to an unrelated party in a private transaction, the proceeds of which were used to redeem shares of common stock payable to an executive officer. In 2016, the Company issued 33,333 shares of common stock, valued at $110,000, to Shadron Stastney in connection with the settlement of litigation. The Company issued 34,585 shares of common stock in 2016 in connection with the cashless exercise of stock options granted in prior years that were about to expire in 2016. In 2015, the Company agreed to grant 65,868 fully vested shares of its common stock to two executive officers as bonuses. These shares were not issued at the time, but were recorded as stock payable. The obligation to issue these shares was redeemed for cash in 2016 for a total payment of $232,602. In 2015, the Company entered into a new capital markets advisory agreement covering a one-year period, which called for 30,000 shares of common stock to be issued as compensation. The first 15,000 shares were issued in September 2015 and valued at $41,400. These shares were amortized over a six-month period. The agreement was cancelled in 2016 and the remaining 15,000 shares were not issued. In 2014, the Company agreed to grant 112,500 shares of common stock to two executive officers at the time as bonuses based on their efforts to recapitalize the Company. Stock-based compensation related to these bonuses of $570,375 was recorded during the year ended December 31, 2014. These shares were not issued at the time and were recorded as stock payable. The obligation to issue these shares was redeemed in 2016 for cash payments of $397,038. Also in 2014, as part of a capital raise, the Company agreed to grant 66,667 shares of common stock to three executive officers at the time. The shares were part of an equity raise and the issuance was recorded as part of equity issuance costs, so no expense was recorded. In 2016, a total of 50,000 of those shares were redeemed for a cash payment of $177,275 and the remaining 16,667 shares were issued to a former executive officer. The Board of Directors of the Company approved a one for three reverse stock split that became effective May 14, 2018. The effect of this reverse stock split has been retroactively reflected in these financial statements.

Warrants

12 Months Ended

Dec. 31, 2017

Warrants [Abstract]

WARRANTS

NOTE 12 –WARRANTS

The Company has issued warrants to purchase common stock, primarily in connection with capital raising activities. As discussed in Note 10, in connection with the strategic investment by WPP, in 2015 the Company issued warrants to purchase 80,148 shares of common stock with an exercise price of $2.3625 per share.

The Company had the following warrants, with an intrinsic value of $485,678, outstanding as of December 31, 2017:

Number of Shares Underlying Warrants	Exercise Price	Expiration Date
268,046	$3.60	03/17/2019
80,148	$2.3625	09/24/2020

The Company had the following warrant activity during the years ended December 31, 2017 and 2016:

	Number of Shares Underlying Warrants			Weighted average exercise price
Outstanding, January 1, 2016		698,194		$	4.95
Granted		-			-
Expired		(16,667	)	$	2.67
Balance, December 31, 2016		681,527		$	5.01
Granted		-			-
Expired		(333,333	)	$	6.75
Balance, December 31, 2017		348,194		$	3.33

Major Customers	12 Months Ended
Major Customers	Dec. 31, 2017
Major Customers [Abstract]
MAJOR CUSTOMERS	NOTE 13 – MAJOR CUSTOMERS The Company had one customer that individually accounted for approximately 12% of revenue in 2017 and a different customer that individually accounted for approximately 12% of revenue in 2016. No other customers accounted for more than 10% of revenue in either year presented.

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Taxes [Abstract]

INCOME TAXES

NOTE 14 – INCOME TAXES

As of December 31, 2017, the Company had net operating loss carry forwards of approximately $12.2 million that expire from 2027 through 2037 that are available to offset future taxable income. The Company was formed in 2006 as a limited liability company and changed to a corporation in 2007. Activity prior to incorporation is not reflected in the Company’s corporate tax returns. In the future, the cumulative net operating loss carry-forward for income tax purposes may differ from the cumulative financial statement loss due to timing differences between book and tax reporting.

The provision for Federal income tax consists of the following for the years ended December 31, 2017 and 2016:

	2017			2016
Federal income tax benefit attributable to:
Current operations	$	715,000		$	523,000
Permanent and timing differences (net)		(280,000	)		133,000
Tax rate change		(1,600,000	)		-
Valuation allowance		1,165,000			(656,000	)
Net provision for federal income tax	$	-		$	-

The cumulative tax effect at the expected rate of 34%, as of December 31, 2016, and 21% as of December 31, 2017, of significant items comprising our net deferred tax amount is as follows as of December 31, 2017 and 2016:

	2017			2016
Deferred tax asset attributable to:
Net operating loss carryover	$	2,551,000		$	3,648,000
Depreciation and amortization		98,000			126,000
Stock compensation		372,000			339,000
Other		-			73,000
Valuation allowance		(3,021,000	)		(4,186,000	)
Net deferred tax asset	$	-		$	-

Under certain circumstances issuance of common shares can result in an ownership change under Internal Revenue Code Section 382 which limits the Company’s ability to utilize carry forwards from prior to the ownership change. Any such ownership change resulting from stock issuances and redemptions could limit the Company’s ability to utilize any net operating loss carry forwards or credits generated before this change in ownership. These limitations can limit both the timing of usage of these laws, as well as the loss of the ability to use these net operating losses. It is likely that fundraising activities have resulted in such an ownership change.

Retirement Plan	12 Months Ended
Retirement Plan	Dec. 31, 2017
Retirement Plan [Abstract]
RETIREMENT PLAN	NOTE 16 – RETIREMENT PLAN The Company sponsors a defined contribution 401(k) profit sharing plan which was adopted in December 2015, effective in January 2016. Under the terms of the plan, the Company matches 100% of the first 3% of payroll contributed by the employee and 50% of the next 2% of payroll contributed by the employee to a maximum of 4% of an employee’s payroll. There was expense of $137,858 and $64,690 recorded in 2017 and 2016, respectively, for company contributions to the plan.

Subsequent Events	3 Months Ended	12 Months Ended
Subsequent Events	Mar. 31, 2018	Dec. 31, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 7 – SUBSEQUENT EVENTS In May 2018, we signed an agreement to issue 1,666,669 shares of common stock for gross proceeds of $9.0 million, with expected net proceeds of approximately $8.3 million. The transaction closed May 4, 2018. In addition, our Board of Directors approved a 1 for 3 stock split to meet the requirements of NASDAQ. The reverse split was effective May 14, 2018. These effective of this reverse split has been retroactively included in these financial statements.	NOTE 17 – SUBSEQUENT EVENTS In February 2018, the Company’s Board of Directors amended the 2013 Equity Compensation Plan to increase the number of shares authorized under the plan to 1,833,333. At the same time, the Company granted 130,000 shares of restricted common stock to officers and options to purchase 106,667 shares of common stock with an exercise price of $4.20 to non-officers, both of which vest only if the Company achieves certain stretch revenue goals in either 2019 or 2020. In addition, the Company accelerated vesting to 2018 on 100,000 existing options that previously vested in 2021.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2017

Summary of Significant Accounting Policies [Abstract]

Basis of Presentation

Principles of Consolidation

Cash and Cash Equivalents

For purposes of the accompanying financial statements, the Company considers all highly liquid instruments with an initial maturity of three months or less to be cash equivalents.

Fair Value of Financial Instruments

Level 1 – Inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

Accounts Receivable and Allowance for Doubtful Accounts

Property and Equipment

Intangible Assets

Revenue Recognition and Revenue Share Expense

Income Taxes

Use of Estimates

Concentration of Credit Risks

Research and Development

Share-based Payments

	2017	2016

Expected dividend yield	0%	0%
Risk free interest rate	1.47% - 1.81%	0.86%-1.15%
Expected option term	3.5 – 5 years	4.5 years
Turnover/forfeiture rate	0%	0%
Expected volatility	65%-78%	91% - 99%

Loss Per Common and Common Equivalent Share

	2017		2016

Options		1,368,750		1,040,000
Warrants		348,194		681,528
Weighted average exercise price	$	3.18	$	4.02

Impairment of Long-Lived Assets

Recently Issued Accounting Guidance

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Summary of Significant Accounting Policies [Abstract]

Schedule of fair value method to account for stock-based compensation

	2017	2016

Expected dividend yield	0%	0%
Risk free interest rate	1.47% - 1.81%	0.86%-1.15%
Expected option term	3.5 – 5 years	4.5 years
Turnover/forfeiture rate	0%	0%
Expected volatility	65%-78%	91% - 99%

Summary of options and warrants outstanding

	2017		2016

Options		1,368,750		1,040,000
Warrants		348,194		681,528
Weighted average exercise price	$	3.18	$	4.02

Prepaid Expenses (Tables)

12 Months Ended

Dec. 31, 2017

Prepaid Expenses [Abstract]

Schedule of prepaid expenses

	2017		2016
Insurance	$	43,764	$	43,608
Rent		8,539		7,212
EHR access fees		203,125		-
Legal		-		30,000
Total prepaid expenses	$	255,428	$	80,820

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2017

Property and Equipment [Abstract]

Schedule of property and equipment

	2017		2016
Computer equipment	$	83,079	$	66,433
Furniture and fixtures		158,502		132,905
Subtotal		241,581		199,338
Accumulated depreciation		74,276		(25,689	)
Property and equipment, net	$	167,305	$	173,649

Web-Based Technology (Tables)

12 Months Ended

Dec. 31, 2017

Web-Based Technology [Abstract]

Schedule of capitalized costs in developing web-based technology

	2017			2016
OptimizeRx consumer web-based technology	$	154,132		$	154,133
OptimizeRx EHR integrated technology		1,304,230			1,304,230
Subtotal		1,458,362			1,458,363
Accumulated amortization		(1,314,632	)		(1,106,559	)
Web-based technology, net	$	143,730		$	351,804

Patent and Trademarks (Tables)

12 Months Ended

Dec. 31, 2017

Patent and Trademarks [Abstract]

Schedule of patent and trademarks

	2017			2016
Patent rights and intangible assets	$	930,000		$	930,000
Patent defense costs		172,457			172,457
New patents and trademarks		-			65,738
Subtotal		1,102,457			1,168,165
Accumulated amortization		(463,691	)		(395,801	)
Patent rights and intangible assets, net	$	638,766		$	772,394

Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2017

Schedule of sets forth the activity between the Company and WPP

	2017		2016
Total billings to WPP Agencies	$	3,554,168	$	2,613,942
Revenue recognized from WPP Agencies	$	3,696,214	$	1,542,411
Accounts receivable from WPP Agencies	$	1,173,614	$	1,108,585
Rebates given to WPP Agencies	$	33,249	$	24,519
Marketing services purchased from WPP Agencies	$	54,762	$	190,686
Accounts payable to WPP Agencies	$	-	$	12,600
Revenue share expense recorded to WPP Agencies	$	401,596	$	177,372
Revenue share expenses owed to WPP Agencies	$	447,670	$	127,458

Share Based Payments - Options (Tables)

12 Months Ended

Dec. 31, 2017

Share Based Payments - Options [Abstract]

Schedule of option activity

	Number of Options			Weighted average exercise price		Weighted average remaining contractual life (years)		Aggregate intrinsic value $
Outstanding, January 1, 2016		538,333		$	3.27
Granted - 2016		680,000		$	3.27
Exercised - 2016		(161,666	)	$	2.67
Expired – 2016		(16,667	)	$	3.24
Outstanding, December 31, 2016		1,040,000		$	3.36		3.6
Granted – 2017		480,417		$	2.88
Exercised – 2017		(43,333	)	$	3.81
Expired – 2017		(108,334	)	$	4.02
Outstanding, December 31, 2017		1,368,750		$	3.12		3.2	$	2,173,700
Exercisable, December 31, 2017		630,417		$	3.06		2.9	$	1,035,900

Schedule of expiration date and exercise price of the options outstanding

Number of Options	Exercise Price	Expiration Date
200,000	$2.46	03/31/22
50,000	$3.00	10/30/18
378,333	$3.15	03/03/19
500,000	$3.21	02/22/21
166,667	$3.45	07/28/21
6,667	$3.51	11/01/22
33,333	$3.66	03/03/19
10,417	$4.71	12/31/22
3,333	$5.55	01/29/19

Warrants (Tables)

12 Months Ended

Dec. 31, 2017

Warrants [Abstract]

Schedule of warrants outstanding

Number of Shares Underlying Warrants	Exercise Price	Expiration Date
268,046	$3.60	03/17/2019
80,148	$2.3625	09/24/2020

Schedule of warrant activity

	Number of Shares Underlying Warrants			Weighted average exercise price
Outstanding, January 1, 2016		698,194		$	4.95
Granted		-			-
Expired		(16,667	)	$	2.67
Balance, December 31, 2016		681,527		$	5.01
Granted		-			-
Expired		(333,333	)	$	6.75
Balance, December 31, 2017		348,194		$	3.33

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Taxes [Abstract]

Schedule of federal income tax benefit

	2017			2016
Federal income tax benefit attributable to:
Current operations	$	715,000		$	523,000
Permanent and timing differences (net)		(280,000	)		133,000
Tax rate change		(1,600,000	)		-
Valuation allowance		1,165,000			(656,000	)
Net provision for federal income tax	$	-		$	-

Schedule of deferred tax assets

	2017			2016
Deferred tax asset attributable to:
Net operating loss carryover	$	2,551,000		$	3,648,000
Depreciation and amortization		98,000			126,000
Stock compensation		372,000			339,000
Other		-			73,000
Valuation allowance		(3,021,000	)		(4,186,000	)
Net deferred tax asset	$	-		$	-

Contingencies (Tables)

12 Months Ended

Dec. 31, 2017

Contingencies [Abstract]

Schedule of minimum annual rent payments

Year ended December 31:
2018		75,772
2019		70,224
Total lease commitment	$	145,996

Nature of Business and Basis of Presentation (Details) - shares	Apr. 14, 2008	Mar. 31, 2018
Nature of Business and Basis of Presentation (Textual)
Shares issued by RFID, Ltd. pursuant to a share exchange agreement	1,256,958
Percentage of stock of owned by RFID	100.00%	20.00%

New Financial Accounting Standards (Details) - USD ($)	3 Months Ended
New Financial Accounting Standards (Details) - USD ($)	Mar. 31, 2018	Jan. 01, 2018
New Financial Accounting Standards (Textual)
Increase in deferred revenue		$ 142,027
New revenue accounting standard, description	The new revenue standard not taken effect, our revenues for the period would have been higher by $117,911 and deferred revenues lower by $117,911.

- Definition

Disclosure related to a new accounting pronouncement or a change in accounting principle, including the nature and reason for the change and the effect of the change on prior periods and the current period.

+ References + Details

Stockholders' Equity (Details) - USD ($)	3 Months Ended		12 Months Ended
Stockholders' Equity (Details) - USD ($)	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2016
Stockholders' Equity (Textual)
Issuance of common stock: for cash	$ 447,000		$ 449,500
Diluted loss per common share	604,172
Independent Directors [Member]
Stockholders' Equity (Textual)
Additional shares issued	6,250	6,250
Compensation plan issuance of shares	6,250	6,250
Compensation plan issuance, value	$ 28,875	$ 15,375

Share Based Payments - Options (Details) - Stock Options [Member] - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Number of Options
Begining balance, Outstanding	1,040,000	538,333
Granted	480,417	680,000
Exercised	(43,333)	(161,666)
Expired	(108,334)	(16,667)
Ending balance, Outstanding	1,368,750	1,040,000
Exercisable	630,417
Weighted average exercise price
Beginning balance, Outstanding	$ 3.36	$ 3.27
Granted	2.88	3.27
Exercised	3.81	2.67
Expired	4.02	3.24
Ending balance, Outstanding	3.12	$ 3.36
Exercisable	$ 3.06
Outstanding, Weighted average remaining contractual life (years)	3 years 2 months 12 days	3 years 7 months 6 days
Exercisable, Weighted average remaining contractual life (years)	2 years 10 months 25 days
Outstanding, Aggregate intrinsic value	$ 2,173,700
Exercisable, Aggregate intrinsic value	$ 1,035,900

Share Based Payments - Options (Details 1)	12 Months Ended
Share Based Payments - Options (Details 1)	Dec. 31, 2017 $ / shares shares
Options One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	200,000
Exercise Price \| $ / shares	$ 2.46
Expiration Date	Mar. 31, 2022
Options Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	50,000
Exercise Price \| $ / shares	$ 3.00
Expiration Date	Oct. 30, 2018
Options Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	378,333
Exercise Price \| $ / shares	$ 3.15
Expiration Date	Mar. 03, 2019
Options Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	500,000
Exercise Price \| $ / shares	$ 3.21
Expiration Date	Feb. 22, 2021
Options Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	166,667
Exercise Price \| $ / shares	$ 3.45
Expiration Date	Jul. 28, 2021
Options Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	6,667
Exercise Price \| $ / shares	$ 3.51
Expiration Date	Nov. 01, 2022
Options Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	33,333
Exercise Price \| $ / shares	$ 3.66
Expiration Date	Mar. 03, 2019
Options Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	10,417
Exercise Price \| $ / shares	$ 4.71
Expiration Date	Dec. 31, 2022
Options Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	3,333
Exercise Price \| $ / shares	$ 5.55
Expiration Date	Jan. 29, 2019

Share Based Payments - Options (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share Based Payments - Options (Textual)
Options outstanding				8,333
Compensation cost			$ 815,014	$ 384,126
Compensation expense			$ 87,375	$ 175,175
Stock Option [Member]
Share Based Payments - Options (Textual)
Compensation expense	$ 468,247	$ 114,069
Increased shares of common stock authorized	1,833,333
2013 Equity Compensation Plan [Member]
Share Based Payments - Options (Textual)
Shares reserved for issuance			500,000
Share-based compensation plan, description			The Plan was amended in 2016 to increase the authorized shares to 1,333,333 shares and again in 2018 to increase the authorized shares to 1,833,333.
Options outstanding				1,368,750
Shares redeemed				228,338
Restricted shares					245,035	245,035
Additional shares issued				16,667
Options expired			Dec. 31, 2017
Non-vested shares				633,333
Weighted average contractual life				1 year 1 month 6 days
Options exercisable				406,667

Related Party Transactions (Details) - USD ($)	12 Months Ended
Related Party Transactions (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Total billings to WPP Agencies [Member]
Related Party Transaction [Line Items]
Related party transactions	$ 3,554,168	$ 2,613,942
Revenue recognized from WPP Agencies [Member]
Related Party Transaction [Line Items]
Related party transactions	3,696,214	1,542,411
Accounts receivable from WPP Agencies [Member]
Related Party Transaction [Line Items]
Related party transactions	1,173,614	1,108,585
Rebates given to WPP Agencies [Member]
Related Party Transaction [Line Items]
Related party transactions	33,249	24,519
Marketing services purchased from WPP Agencies [Member]
Related Party Transaction [Line Items]
Related party transactions	54,762	190,686
Accounts payable to WPP Agencies [Member]
Related Party Transaction [Line Items]
Related party transactions		12,600
Revenue share expense recorded to WPP Agencies
Related Party Transaction [Line Items]
Related party transactions	401,596	177,372
Revenue share expenses owed to WPP Agencies [Member]
Related Party Transaction [Line Items]
Related party transactions	$ 447,670	$ 127,458

Related Party Transactions (Details Textual) - USD ($)	12 Months Ended
Related Party Transactions (Details Textual) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2010	Mar. 31, 2018	Dec. 31, 2015	Apr. 14, 2008
Related Party Transactions (Textual)
Shares payable redeemed for cash	$ (390,000)	$ (599,915)
Percentage of ownership				20.00%		100.00%
CEO [Member]
Related Party Transactions (Textual)
Shares issued for in connection with purchase of a patent			100,000
Stock options			66,667
Expire date			Apr. 30, 2015
Shares values			$ 360,000
Shares payable redeemed for cash		$ 363,000
Payable to the related party			$ 570,000
Percentage of ownership					20.00%

Contingencies (Details)	Dec. 31, 2017 USD ($)
Year ended December 31:
2018	$ 75,772
2019	70,224
Total lease commitment	$ 145,996

Contingencies (Details Textual)	12 Months Ended
Contingencies (Details Textual)	Dec. 31, 2017 USD ($)
Contingencies (Textual)
Contingent liabilities related to audit fees in percentage	10.00%
Allscripts agreement payment	$ 900,000
Description of new leasing arrangements	The current lease is a three-year lease beginning December 1, 2016, with options for up to an additional 6 years. The rent is payable monthly at rates of $6,232, $6,308, and $6,384 per month for years 1, 2, and 3 of the lease, respectively. The monthly rates for the option years range from $6,384 per month to $6,688 per month for the option years 4 through 9 of the lease. If the Company fails to exercise its option for option years 4 and 5, a least termination payment of $7,300 will be due at the end of the initial 3-year term.
Lease expiration date	Nov. 30, 2016
Operating lease payable	$ 2,700
Operating leases rent expense	1,370
Allscripts payment of remaining amount	325,000
Additional payment of termination	$ 220,440
Description of administer and software	The Company has an agreement with a third party to host and administer its software through March 31, 2018 at a rate of $24,230 per month for a total of $72,690 for the three-month period.
Installment 1 [Member]
Contingencies (Textual)
Allscripts agreement payment	$ 250,000
Installment 2 [Member]
Contingencies (Textual)
Allscripts agreement payment	$ 650,000

Summary of Significant Accounting Policies (Details)	12 Months Ended
Summary of Significant Accounting Policies (Details)	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology
Expected dividend yield	0.00%	0.00%
Risk free interest rate minimum	1.47%	0.86%
Risk free interest rate maximum	1.81%	1.15%
Expected option term		4 years 6 months
Turnover/forfeiture rate	0.00%	0.00%
Expected volatility minimum	65.00%	91.00%
Expected volatility maximum	78.00%	99.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology
Expected option term	3 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology
Expected option term	5 years

Summary of Significant Accounting Policies (Details 1) - Warrant [Member] - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Summary Of Significant Accounting Policies [Line Items]
Options	1,368,750	1,040,000
Warrants	348,194	681,528
Weighted average exercise price	$ 3.18	$ 4.02

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Summary of Significant Accounting Policies (Textual)
Bad debt expense	$ 0	$ 0
Allowance for doubtful accounts	$ 0	$ 0
Revenue recognition and revenue shares, Description	Legal settlement in an amount equal to the greater of 10% of financial messaging distribution revenues generated through the network, or $0.37 per financial message distributed.
Number of common shares potentially issuable upon the exercise of certain options and warrants	163,067
Patents [Member]
Summary of Significant Accounting Policies (Textual)
Intangible assets amortized over their estimated useful lives	17 years
Computer Equipment [Member]
Summary of Significant Accounting Policies (Textual)
Property and equipment, estimated useful lives	3 years
Minimum [Member] \| Software and Websites [Member]
Summary of Significant Accounting Policies (Textual)
Intangible assets amortized over their estimated useful lives	3 years
Minimum [Member] \| Office Equipment [Member]
Summary of Significant Accounting Policies (Textual)
Property and equipment, estimated useful lives	3 years
Maximum [Member] \| Software and Websites [Member]
Summary of Significant Accounting Policies (Textual)
Intangible assets amortized over their estimated useful lives	4 years
Maximum [Member] \| Office Equipment [Member]
Summary of Significant Accounting Policies (Textual)
Property and equipment, estimated useful lives	5 years

Prepaid Expenses (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Prepaid Expenses [Abstract]
Insurance		$ 43,764	$ 43,608
Rent		8,539	7,212
EHR access fees		203,125
Legal			30,000
Total prepaid expenses	$ 191,413	$ 255,428	$ 80,820

Property and Equipment (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, Subtotal		$ 241,581	$ 199,338
Accumulated depreciation		74,276	(25,689)
Property and equipment, net	$ 157,608	167,305	173,649
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Subtotal		83,079	66,433
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Subtotal		$ 158,502	$ 132,905

Property and Equipment (Details Textual) - USD ($)	12 Months Ended
Property and Equipment (Details Textual) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Property and Equipment (Textual)
Depreciation expense	$ 48,587	$ 22,414

Web-Based Technology (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Web-based technology, Subtotal		$ 1,458,362	$ 1,458,363
Accumulated amortization		(1,314,632)	(1,106,559)
Web-based technology, net	$ 152,493	143,730	351,804
OptimizeRx consumer web-based technology [Member]
Finite-Lived Intangible Assets [Line Items]
Web-based technology, Subtotal		154,132	154,133
OptimizeRx EHR integrated technology [Member]
Finite-Lived Intangible Assets [Line Items]
Web-based technology, Subtotal		$ 1,304,230	$ 1,304,230

Web-Based Technology (Details Textual) - USD ($)	12 Months Ended
Web-Based Technology (Details Textual) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Web-Based Technology (Textual)
Web-based technology amortization period, Description	Amortization is recorded using the straight-line method over periods of up to five years.
Web-based technology, amortization expense	$ 208,074	$ 152,502
Amortization expense 2018	91,039
Amortization expense for 2019	$ 52,691

Patent and Trademarks (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Patent and Trademarks [Abstract]
Patent rights and intangible assets		$ 930,000	$ 930,000
Patent defense costs		172,457	172,457
New patents and trademarks			65,738
Subtotal		1,102,457	1,168,165
Accumulated amortization		(463,691)	(395,801)
Patent rights and intangible assets, net	$ 621,793	$ 638,766	$ 772,394

Patent and Trademarks (Details Textual) - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
Patent and Trademarks (Details Textual) - USD ($)	Jul. 31, 2010	Apr. 26, 2010	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Patent and Trademarks (Textual)
Exchange shares of common stock, value			$ 447,000		$ 449,500
Amortizing patent, Description				Straight-line method
Useful life	17 years
Amortization expense				$ 67,890	$ 67,758
Amortization expense related to patents				$ 67,890
Key Patent [Member]
Patent and Trademarks (Textual)
Exchange shares of common stock		100,000
Exchange shares of common stock, value		$ 570,000
Stock options		66,667
Shares values		$ 360,000

Deferred Revenue (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Deferred Revenue (Textual)
Deferred revenue	$ 856,914	$ 507,160	$ 386,581

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References + Details

Preferred Stock (Details) - $ / shares	12 Months Ended
Preferred Stock (Details) - $ / shares	Dec. 31, 2017	Mar. 31, 2018	Dec. 31, 2016
Preferred Stock (Textual)
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Preferred Stock, par value	$ 0.001	$ 0.001	$ 0.001
Percentage of dividends rate	10.00%
Series A [Member]
Preferred Stock (Textual)
Preferred stock, shares authorized	1,000
Series B [Member]
Preferred Stock (Textual)
Preferred stock, shares authorized	1,000

Common Stock (Details) - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
Common Stock (Details) - USD ($)	Feb. 28, 2018	Sep. 30, 2015	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Common Stock (Textual)
Common stock, shares issued			9,878,944	9,772,694	9,906,289
Common stock, shares outstanding			9,878,944	9,772,694	9,906,289
Common stock value, issued			$ 9,879	$ 9,773	$ 9,906
Common stock issued, values			$ 447,000		449,500
Issuance of common stock for services				$ 87,375	$ 51,375
Common stock, shares authorized			500,000,000	500,000,000	500,000,000
Common stock, par value			$ 0.001	$ 0.001	$ 0.001
Employee bonus, value							$ 112,500
Employee bonus, share							570,375
Shares payable redeemed for cash				$ (390,000)	$ (599,915)
Cash payments of redeemed shares					$ 397,038
Employee Stock Option [Member]
Common Stock (Textual)
Options, exercises in period				8,071
Stock Option [Member]
Common Stock (Textual)
Common stock issued, shares					34,585
New Capital Markets Advisory Agreement Shares Issued First [Member]
Common Stock (Textual)
Common stock, shares issued						30,000
Common stock issued, shares		15,000
Sale of common stock value		$ 41,400
Number of shares not issued					15,000
Former Executive Officer [Member]
Common Stock (Textual)
Shares granted					16,667
Redeem shares for cash, shares					50,000
Shares payable redeemed for cash					$ 177,275
Three executive officers [Member]
Common Stock (Textual)
Shares granted							66,667
Directors [Member]
Common Stock (Textual)
Shares granted				25,000	16,667
Granted value				$ 87,375	$ 51,375
Total payment	$ 130,000
Two executive officers [Member]
Common Stock (Textual)
Employee bonus, share						65,868
Shares payable redeemed for cash					$ 232,602
Unrelated party [Member]
Common Stock (Textual)
Common stock issued, shares					128,063
Shadron Stastney [Member]
Common Stock (Textual)
Common stock issued, values					$ 110,000
Common stock issued, shares					33,333
Chief Executive Officer [Member]
Common Stock (Textual)
Purchased and cancelled shares				166,666
Total payment				$ 390,000
Per share price				$ 2.34

Warrants (Details)	12 Months Ended
Warrants (Details)	Dec. 31, 2017 $ / shares shares
Warrant [Member]
Number of Shares Underlying Warrants \| shares	268,046
Exercise price \| $ / shares	$ 3.60
Expiration date	Mar. 17, 2019
Warrant One [Member]
Number of Shares Underlying Warrants \| shares	80,148
Exercise price \| $ / shares	$ 2.3625
Expiration date	Sep. 24, 2020

Warrants (Details 1) - Warrant [Member] - $ / shares	12 Months Ended
Warrants (Details 1) - Warrant [Member] - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Number of Shares Underlying Warrants
Beginning balance	681,527	698,194
Granted
Expired	(333,333)	(16,667)
Ending balance	348,194	681,527
Weighted average exercise price
Beginning Balance	$ 5.01	$ 4.95
Granted
Expired	6.75	2.67
Ending Balance	$ 3.33	$ 5.01

Warrants (Details Textual) - Warrant [Member]	12 Months Ended
Warrants (Details Textual) - Warrant [Member]	Dec. 31, 2017 USD ($) $ / shares shares
Warrants (Textual)
Issued warrants to purchase \| shares	80,148
Granted, weighted average \| $ / shares	$ 2.3625
Warrants intrinsic value of outstanding \| $	$ 485,678

Major Customers (Details)	12 Months Ended
Major Customers (Details)	Dec. 31, 2017	Dec. 31, 2016
Major Customers (Textual)
Concentration Risk Percentage Total	10.00%
Customer [Member]
Major Customers (Textual)
Revenues Percentage	12.00%	12.00%

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Federal income tax benefit attributable to:
Current operations	$ 715,000	$ 523,000
Permanent and timing differences (net)	(280,000)	133,000
Tax rate change	(1,600,000)
Valuation allowance	1,165,000	(656,000)
Net provision for federal income tax

Income Taxes (Details 1) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Deferred tax asset attributable to:
Net operating loss carryover	$ 2,551,000	$ 3,648,000
Depreciation and amortization	98,000	126,000
Stock compensation	372,000	339,000
Other		73,000
Valuation allowance	(3,021,000)	(4,186,000)
Net deferred tax asset

Income Taxes (Details Textual) - USD ($) $ in Millions	12 Months Ended
Income Taxes (Details Textual) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Income Taxes (Textual)
Net operating loss carryforwards	$ 12.2
Net operating loss expire, description	Expire from 2027 through 2037 that are available to offset future taxable income.
Cumulative tax effect at rate	21.00%	34.00%

Retirement Plan (Details) - USD ($)	12 Months Ended
Retirement Plan (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Retirement Plan (Textual)
Defined benefit plan, description	The terms of the plan, the Company matches 100% of the first 3% of payroll contributed by the employee and 50% of the next 2% of payroll contributed by the employee to a maximum of 4% of an employee's payroll.
Defined contribution plan, administrative expense	$ 137,858	$ 64,690

Subsequent Events (Details) - USD ($)	1 Months Ended		12 Months Ended
Subsequent Events (Details) - USD ($)	May 31, 2018	Feb. 28, 2018	Dec. 31, 2017	Dec. 31, 2016
Subsequent Events (Textual)
Net proceeds of common stock amount				$ 449,500
Directors [Member]
Subsequent Events (Textual)
Number of shares authorized increased		$ 1,833,333
Restricted common stock to officers		$ 130,000
Options to purchase of common stock		106,667
Options to purchase, exercise price		4.20
Existing options that previously vested, description		The Company accelerated vesting to 2018 on 100,000 existing options that previously vested in 2021.
Subsequent Event [Member]
Subsequent Events (Textual)
Common stock issued, Shares	1,666,669
Gross proceeds of common stock amount	$ 9,000,000
Net proceeds of common stock amount	$ 8,300,000
Stock split	1 for 3